Molecular Partners AG

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 23, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that late-breaker data of the EMPATHY study of ensovibep will be presented by Dr. N. Kumarasamy, Chief and Director, VHS-Infectious Diseases Medical Centre, Chennai, India, at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held as a hybrid congress in Lisbon, Portugal, from April 23-26, 2022.

Molecular Partners Announces Presentation of the EMPATHY Study of Ensovibep for the Treatment of COVID-19 at ECCMID 2022

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG  (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the company's Chief Financial Officer, Andreas Emmenegger, and Chief Operating Officer, Michael Stumpp, will participate in the upcoming Kempen Life Sciences investor conference on April 20 & 21, 2022.

Molecular Partners to Present at Kempen Life Sciences Investor Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the shareholders of the Company approved all motions proposed by the Board of Directors.

Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the publication of preclinical data from MP0317 in Cancer Immunology Research, a journal of the American Association for Cancer Research. MP0317 is the Company's second immuno-oncology program to enter clinical studies and is designed to target both FAP (fibroblast activation protein), a protein found in high density around tumors, and the immunostimulatory protein CD40, to enable tumor-localized immune activation.

Molecular Partners Announces Publication of Preclinical Data from CD40 Therapeutic Candidate MP0317 in Cancer Immunology Research

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2022.

Molecular Partners Publishes Invitation to Annual General Meeting 2022

Molecular Partners AG (MOLN) CEO Patrick Amstutz on Q4 2021 Results - Earnings Call Transcript

Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG  (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in two upcoming healthcare investor events in March, 2022. In addition, the Company will publish its full year 2021 annual report on March 15 and hold an investor conference call on March 16, 2021.

Molecular Partners to Present at Upcoming Healthcare Investor Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG  (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the SVB Leerink 11th Annual Global Healthcare Conference 2022. The presentation will take place on Wednesday, February 16, at 9:20 am ET.

Molecular Partners to Present at Upcoming Healthcare Investor Conference

Novartis

Molecular Partners AG MOLN and its partner Novartis AG NVS, have requested FDA Emergency Use Authorization (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, was informed by its partner Novartis that the company has requested Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19.

Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19

Digital World Acquisition Corp

Exxon Mobil

3 Stocks That Have Soared as the Market Sank: Are They Buys Now?

Novartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep.

Novartis Hopes to Have Another COVID Therapy on the Way

ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR:

Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19

BVF Partners L.P. acquired shares from Essex Woodlands Health Ventures Funds BVF Partners L.P. acquired shares from Essex Woodlands Health Ventures Funds

Molecular Partners Reports Disclosure of Major Shareholder as per Swiss Stock Exchange Regulations

The company had some very good news to deliver about its coronavirus drug candidate.

Why Molecular Partners Stock Crushed the Market Today

The stock price of Molecular Partners AG (NASDAQ: MOLN) increased by over 35% pre-market today. This is why it happened.

Molecular Partners Stock (MOLN): Why The Price Surged Today

After getting positive trial data, Novartis AG (NYSE: NVS) said it would in-license a new drug developing with Molecular Partners AG (NASDAQ: MOLN) to treat COVID-19. Novartis will pay CHF 150 million to in-license ensovibep from Molecular Partners.

Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage Data

Novartis says it will license antiviral Covid-19 treatment ensovibep from Molecular Partners following positive trial results.

Molecular Partners Stock Surges as Novartis Plans to License Covid-19 Drug

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Novartis today announced that Part A of the EMPATHY clinical trial1, that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo to treat COVID-19, met the primary endpoint of viral load reduction over eight days. The two secondary endpoints also showed clinically meaningful benefit over placebo – (1) composite endpoint of hospitalization and/or Emergency Room (ER) visits or death, and (2) time to sustained clinical recovery. Novartis confirms it will now exercise its option to in-license ensovibep from Molecular Partners and, following exercise of the option, will seek expedited access globally, first via the FDA's EUA process.

Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19

Basel, January 10, 2022 — Novartis and Molecular Partners today announced that Part A of the EMPATHY clinical trial1 that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo to treat COVID-19, met the primary endpoint of viral load reduction over eight days. The two secondary endpoints also showed clinically meaningful benefit over placebo – (1) composite endpoint of hospitalization and/or Emergency Room (ER) visits or death, and (2) time to sustained clinical recovery. Novartis confirms it will now exercise its option to in-license ensovibep from Molecular Partners and, following exercise of the option, will seek expedited access globally, first via the FDA's EUA process.

Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19

The consensus price target hints at a 96.3% upside potential for Molecular Partners AG Sponsored ADR (MOLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 96% Upside in Molecular Partners AG Sponsored ADR (MOLN): Can the Stock Really Move This High?

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Senior Management and invited guests will host a virtual Oncology R&D Day.

Molecular Partners to Host Oncology Day (Virtual)

Molecular Partners AG (NASDAQ: MOLN) entered into a license agreement with Novartis AG (NYSE: NVS) to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies (DARPin-RLTs). According to the license agreement, Novartis will pay $20 million upfront to Molecular Partners.

Molecular Partners Inks License Deal With Novartis For $580M

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR:

News for Molecular Partners AG Stock (MOLN)